Sino Biopharmaceutical ( (HK:1177) ) has issued an update.
Sino Biopharmaceutical Limited announced that it will present 45 research results at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including 12 oral sessions and 4 Late-Breaking Abstracts. This participation highlights the company’s ongoing commitment to advancing cancer treatment, potentially enhancing its industry standing and offering significant insights for stakeholders involved in oncology research and development.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the biopharmaceutical industry. It is involved in the research and development of pharmaceutical products, with a particular emphasis on treatments for cancer and other serious diseases.
YTD Price Performance: 26.41%
Average Trading Volume: 2,117
Technical Sentiment Signal: Sell
Current Market Cap: $9.23B
For a thorough assessment of 1177 stock, go to TipRanks’ Stock Analysis page.